{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:07:30Z","timestamp":1792728450120,"version":"4.5.0"},"reference-count":136,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,20]],"date-time":"2021-06-20T00:00:00Z","timestamp":1624147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jaip.2021.06.011","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T03:47:23Z","timestamp":1624333643000},"page":"3918-3928","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"title":["Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review"],"prefix":"10.1016","volume":"9","author":[{"given":"Theo","family":"G\u00fclen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Akin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Bonadonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Siebenhaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigurd","family":"Broesby-Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut","family":"Brockow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Niedoszytko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boguslaw","family":"Nedoszytko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke N.G.","family":"Oude Elberink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph H.","family":"Butterfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang R.","family":"Sperr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Alvarez-Twose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Horny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Sotlar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Schwaab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Jawhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Zanotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan J.","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody C.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy I.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Orfao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Triggiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Arock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence B.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean D.","family":"Metcalfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2021.06.011_bib1","first-page":"13","article-title":"The mast cell: a multifunctional effector cell","volume":"7","author":"Crivellato","year":"2003","journal-title":"Adv Clin Path"},{"key":"10.1016\/j.jaip.2021.06.011_bib2","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1146\/annurev.immunol.21.120601.141025","article-title":"Mast cells as \"tunable\" effector and immunoregulatory cells: recent advances","volume":"23","author":"Galli","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/978-1-4419-9533-9_1","article-title":"Mast cell biology: introduction and overview","volume":"716","author":"Gilfillan","year":"2011","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.jaip.2021.06.011_bib4","doi-asserted-by":"crossref","first-page":"10743","DOI":"10.7150\/thno.46719","article-title":"Mast cells as a unique hematopoietic lineage and cell system: from Paul Ehrlich's visions to precision medicine concepts","volume":"10","author":"Valent","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.jaip.2021.06.011_bib5","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3390\/ijms21020464","article-title":"Mast cells: fascinating but still elusive after 140 years from their discovery","volume":"21","author":"Varricchi","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaip.2021.06.011_bib6","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.iac.2006.05.005","article-title":"Mast cell mediators in allergic inflammation and mastocytosis","volume":"26","author":"Castells","year":"2006","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2021.06.011_bib7","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1002\/eji.201040559","article-title":"Mast cells in allergy and infection: versatile effector and regulatory cells in innate and adaptive immunity","volume":"40","author":"Galli","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jdermsci.2007.09.009","article-title":"Mast cells: versatile regulators of inflammation, tissue remodeling, host defense and homeostasis","volume":"49","author":"Galli","year":"2008","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.jaip.2021.06.011_bib9","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jaci.2006.04.015","article-title":"Molecular regulation of mast cell activation","volume":"117","author":"Rivera","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cellsig.2007.10.013","article-title":"Kit- and Fc epsilonRI-induced differential phosphorylation of the transmembrane adaptor molecule NTAL\/LAB\/LAT2 allows flexibility in its scaffolding function in mast cells","volume":"20","author":"Iwaki","year":"2008","journal-title":"Cell Signal"},{"key":"10.1016\/j.jaip.2021.06.011_bib11","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jaip.2019.09.038","article-title":"MRGPRX2 signaling and skin test results","volume":"8","author":"Kelso","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.06.011_bib12","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0065-2776(08)60879-2","article-title":"Cell surface structures on human basophils and mast cells: biochemical and functional characterization","volume":"52","author":"Valent","year":"1992","journal-title":"Adv Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJMra1409760","article-title":"Mast cells, mastocytosis, and related disorders","volume":"373","author":"Theoharides","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.06.011_bib14","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1398-9995.2005.00785.x","article-title":"Epidemiology of life-threatening and lethal anaphylaxis: a review","volume":"60","author":"Moneret-Vautrin","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.06.011_bib15","first-page":"281","article-title":"Why do people die of anaphylaxis? A clinical review","volume":"12","author":"Kumar","year":"2005","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib16","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/all.12126","article-title":"Mast cell activation syndromes: definition and classification","volume":"68","author":"Valent","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.06.011_bib17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.anai.2013.02.008","article-title":"Mast cell activation syndromes","volume":"111","author":"Lee","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib18","doi-asserted-by":"crossref","first-page":"871","DOI":"10.3389\/fimmu.2017.00871","article-title":"Beyond IgE\u2013when do IgE-crosslinking and effector cell activation lead to clinical anaphylaxis?","volume":"8","author":"Poulsen","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib19","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2006-06-028100","article-title":"Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with \"idiopathic\" anaphylaxis","volume":"110","author":"Akin","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2021.06.011_bib20","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.annemergmed.2006.01.018","article-title":"Second symposium on the definition and management of anaphylaxis: summary report--second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network symposium","volume":"47","author":"Sampson","year":"2006","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.jaip.2021.06.011_bib21","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000354543","article-title":"World Allergy Organization Anaphylaxis Guidelines: 2013 update of the evidence base","volume":"162","author":"Simons","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib22","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1111\/j.1365-2222.2007.02804.x","article-title":"Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA)","volume":"37","author":"Gonzalez de Olano","year":"2007","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2021.06.011_bib23","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1398-9995.2007.01569.x","article-title":"Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients","volume":"63","author":"Brockow","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.06.011_bib24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/cea.12225","article-title":"High prevalence of anaphylaxis in patients with systemic mastocytosis - a single-centre experience","volume":"44","author":"Gulen","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2021.06.011_bib25","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.2020006157","article-title":"Hereditary alpha tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis","volume":"137","author":"Greiner","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2021.06.011_bib26","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jaci.2010.08.035","article-title":"Mast cell activation syndrome: proposed diagnostic criteria","volume":"126","author":"Akin","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jaci.2011.04.037","article-title":"Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations","volume":"128","author":"Hamilton","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib28","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal","volume":"157","author":"Valent","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib29","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jaci.2019.08.023","article-title":"AAAAI Mast Cell Disorders Committee Work Group Report: mast cell activation syndrome (MCAS) diagnosis and management","volume":"144","author":"Weiler","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib30","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jaip.2019.01.006","article-title":"Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome","volume":"7","author":"Valent","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.06.011_bib31","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1515\/dx-2020-0005","article-title":"Diagnosis of mast cell activation syndrome: a global \"consensus-2","volume":"8","author":"Afrin","year":"2020","journal-title":"Diagnosis (Berl)"},{"key":"10.1016\/j.jaip.2021.06.011_bib32","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1756-8722-4-10","article-title":"Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options","volume":"4","author":"Molderings","year":"2011","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.jaip.2021.06.011_bib33","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.12688\/f1000research.12730.1","article-title":"Risk of solid cancer in patients with mast cell activation syndrome: results from Germany and USA","volume":"6","author":"Molderings","year":"2017","journal-title":"F1000Research"},{"key":"10.1016\/j.jaip.2021.06.011_bib34","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s10620-020-06264-9","article-title":"Mast cell activation syndrome: a primer for the gastroenterologist","volume":"66","author":"Weinstock","year":"2021","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jaip.2021.06.011_bib35","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/0091-6749(88)90005-X","article-title":"Tryptase levels in nasal-lavage fluid as an indicator of the immediate allergic response","volume":"82","author":"Castells","year":"1988","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib36","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1056\/NEJM198706253162603","article-title":"Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis","volume":"316","author":"Schwartz","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.06.011_bib37","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.iac.2006.05.010","article-title":"Diagnostic value of tryptase in anaphylaxis and mastocytosis","volume":"26","author":"Schwartz","year":"2006","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2021.06.011_bib38","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.jaci.2005.12.1356","article-title":"Prolonged elevation of serum tryptase in idiopathic anaphylaxis","volume":"117","author":"Shanmugam","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib39","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0091-6749(06)80017-5","article-title":"Insect-sting challenge in 138 patients: relation between clinical severity of anaphylaxis and mast cell activation","volume":"90","author":"Van der Linden","year":"1992","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib40","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/BF01533368","article-title":"Development of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis","volume":"14","author":"Schwartz","year":"1994","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib41","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0145-2126(01)00020-0","article-title":"Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders","volume":"25","author":"Schwartz","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaip.2021.06.011_bib42","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jaci.2018.06.004","article-title":"Mast cell activation syndrome: importance of consensus criteria and call for research","volume":"142","author":"Valent","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib43","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1111\/all.13226","article-title":"Validation of international consensus equation for acute serum total tryptase in mast cell activation: a perioperative perspective","volume":"72","author":"Baretto","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.06.011_bib44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000501079","article-title":"Why the 20%\u00a0+ 2 tryptase formula is a diagnostic gold standard for severe systemic mast cell activation and mast cell activation syndrome","volume":"180","author":"Valent","year":"2019","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib45","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0145-2126(88)90050-1","article-title":"Establishment of an immature mast cell line from a patient with mast cell leukemia","volume":"12","author":"Butterfield","year":"1988","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaip.2021.06.011_bib46","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000144042","article-title":"Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production","volume":"147","author":"Butterfield","year":"2008","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib47","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.prostaglandins.2010.03.003","article-title":"Increased leukotriene E4 excretion in systemic mastocytosis","volume":"92","author":"Butterfield","year":"2010","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.jaip.2021.06.011_bib48","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jaip.2014.06.011","article-title":"Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11\u03b2-prostaglandin2\u03b1","volume":"2","author":"Ravi","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.06.011_bib49","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/all.12668","article-title":"Urinary 11\u03b2-PGF2\u03b1 and N-methyl histamine correlate with bone marrow biopsy findings in mast cell disorders","volume":"70","author":"Divekar","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.06.011_bib50","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/cea.12914","article-title":"Assessment of in\u00a0vivo mast cell reactivity in patients with systemic mastocytosis","volume":"47","author":"Gulen","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2021.06.011_bib51","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1016\/j.jaip.2020.02.021","article-title":"The utility of measuring urinary metabolites of mast cell mediators in systemic mastocytosis and mast cell activation syndrome","volume":"8","author":"Butterfield","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.06.011_bib52","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.iac.2018.04.011","article-title":"Mast cell mediators of significance in clinical practice in mastocytosis","volume":"38","author":"Butterfield","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2021.06.011_bib53","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF01965102","article-title":"Increased urinary methylimidazoleacetic acid (MelmAA) as an indicator of systemic mastocytosis","volume":"12","author":"Granerus","year":"1982","journal-title":"Agents Actions"},{"key":"10.1016\/j.jaip.2021.06.011_bib54","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1398-9995.2012.02809.x","article-title":"Tryptase and histamine metabolites as diagnostic indicators of indolent systemic mastocytosis without skin lesions","volume":"67","author":"Van Doormaal","year":"2012","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.06.011_bib55","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1056\/NEJM198312293092603","article-title":"Improved diagnosis of mastocytosis by measurement of urinary histamine metabolites","volume":"309","author":"Keyzer","year":"1983","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.06.011_bib56","first-page":"141","article-title":"Markedly increased synthesis of prostaglandin D2 in systemic mastocytosis","volume":"93","author":"Roberts","year":"1980","journal-title":"Trans Assoc Am Physicians"},{"key":"10.1016\/j.jaip.2021.06.011_bib57","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1136\/thx.2004.026641","article-title":"Monitoring mast cell activation by prostaglandin D2 in\u00a0vivo","volume":"59","author":"Dahlen","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2021.06.011_bib58","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jaci.2015.07.001","article-title":"Serum levels of 9\u03b1,11\u03b2-PGF2 and cysteinyl leukotrienes are useful biomarkers of anaphylaxis","volume":"137","author":"Nassiri","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib59","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/0091-6749(94)90371-9","article-title":"Detection of the major urinary metabolite of prostaglandin D2 in the circulation: demonstration of elevated levels in patients with disorders of systemic mast cell activation","volume":"93","author":"Awad","year":"1994","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib60","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2222.2008.03104.x","article-title":"Increased production of cysteinyl leukotrienes and prostaglandin D2 during human anaphylaxis","volume":"39","author":"Ono","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2021.06.011_bib61","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1056\/NEJM198012113032405","article-title":"Increased production of prostaglandin D2 in patients with systemic mastocytosis","volume":"303","author":"Roberts","year":"1980","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.06.011_bib62","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.4049\/jimmunol.164.5.2277","article-title":"Cutting edge: differential production of prostaglandin D2 by human helper T cell subsets","volume":"164","author":"Tanaka","year":"2000","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib63","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1359\/JBMR.041211","article-title":"Production of prostaglandin D(2) by human osteoblasts and modulation of osteoprotegerin, RANKL, and cellular migration by DP and CRTH2 receptors","volume":"20","author":"Gallant","year":"2005","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.jaip.2021.06.011_bib64","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2353\/ajpath.2010.090111","article-title":"Dendritic cells express hematopoietic prostaglandin D synthase and function as a source of prostaglandin D2 in the skin","volume":"176","author":"Shimura","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaip.2021.06.011_bib65","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.4049\/jimmunol.1101806","article-title":"Eosinophils as a novel cell source of prostaglandin D2: autocrine role in allergic inflammation","volume":"187","author":"Luna-Gomes","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib66","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev.bi.52.070183.002035","volume":"52","author":"Hammarstr\u00f6m","year":"1983","journal-title":"Leukotrienes. Annu Rev Biochem"},{"key":"10.1016\/j.jaip.2021.06.011_bib67","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.anai.2013.06.031","article-title":"Lipid mediators and allergic diseases","volume":"111","author":"Fanning","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib68","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJM200402123500723","article-title":"Leukotriene-receptor inhibition for the treatment of systemic mastocytosis","volume":"350","author":"Tolar","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.06.011_bib69","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/S0140-6736(14)60585-7","article-title":"Flushing, fatigue, and recurrent anaphylaxis: a delayed diagnosis of mastocytosis","volume":"383","author":"Gulen","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2021.06.011_bib70","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000237133","article-title":"Cysteinyl leukotriene production in anaphylactic reactions","volume":"108","author":"Denzlinger","year":"1995","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib71","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3109\/08923973.2011.651222","article-title":"Serotonin and its 5-HT1 receptor in human mastocytosis","volume":"34","author":"Ritter","year":"2012","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.jaip.2021.06.011_bib72","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1365-2362.2008.02047.x","article-title":"Clinical correlates of blood serotonin levels in patients with mastocytosis","volume":"38","author":"Kushnir-Sukhov","year":"2008","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jaip.2021.06.011_bib73","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jaci.2012.08.016","article-title":"Platelet-activating factor, histamine, and tryptase levels in human anaphylaxis","volume":"131","author":"Vadas","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib74","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1056\/NEJMoa070030","article-title":"Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis","volume":"358","author":"Vadas","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.06.011_bib75","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.jaip.2017.08.022","article-title":"Chromogranin A is not a biomarker of mastocytosis","volume":"6","author":"Hanjra","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.06.011_bib76","doi-asserted-by":"crossref","first-page":"e0124912","DOI":"10.1371\/journal.pone.0124912","article-title":"Determination of plasma heparin level improves identification of systemic mast cell activation disease","volume":"10","author":"Vysniauskaite","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2021.06.011_bib77","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1517\/14656566.2013.824424","article-title":"Mastocytosis: update on pharmacotherapy and future directions","volume":"14","author":"Cardet","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jaip.2021.06.011_bib78","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/ACI.0000000000000377","article-title":"Pharmacotherapy of mast cell disorders","volume":"17","author":"Gulen","year":"2017","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib79","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/187152806775269303","article-title":"Current options in the treatment of mast cell mediator-related symptoms in mastocytosis","volume":"5","author":"Escribano","year":"2006","journal-title":"Inflamm Allergy Drug Targets"},{"key":"10.1016\/j.jaip.2021.06.011_bib80","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaip.2019.02.002","article-title":"Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management","volume":"7","author":"Castells","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.06.011_bib81","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jaci.2007.03.032","article-title":"Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis","volume":"119","author":"Carter","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib82","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.anai.2014.05.001","article-title":"Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome","volume":"113","author":"Jagdis","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib83","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/all.13237","article-title":"Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: efficacy and safety observations","volume":"73","author":"Broesby-Olsen","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.06.011_bib84","first-page":"3787586","article-title":"Efficacy of omalizumab in indolent systemic mastocytosis","volume":"2019","author":"Slapnicar","year":"2019","journal-title":"Case Rep Hematol"},{"key":"10.1016\/j.jaip.2021.06.011_bib85","doi-asserted-by":"crossref","first-page":"e01075","DOI":"10.1002\/cti2.1075","article-title":"Successful treatment of idiopathic mast cell activation syndrome with low-dose omalizumab","volume":"8","author":"Berry","year":"2019","journal-title":"Clin Transl Immunology"},{"key":"10.1016\/j.jaip.2021.06.011_bib86","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1016\/j.jaip.2019.04.030","article-title":"Omalizumab and mast cell disorders: are we there yet?","volume":"7","author":"Weiler","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.06.011_bib87","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1016\/j.jaip.2019.03.039","article-title":"Omalizumab therapy for mast cell-mediator symptoms in patients with ISM, CM, MMAS, and MCAS","volume":"7","author":"Lemal","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.06.011_bib88","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/cea.12369","article-title":"The presence of mast cell clonality in patients with unexplained anaphylaxis","volume":"44","author":"Gulen","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2021.06.011_bib89","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJM199202273260907","article-title":"Response to interferon alfa-2b in a patient with systemic mastocytosis","volume":"326","author":"Kluin-Nelemans","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.06.011_bib90","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","article-title":"Cladribine therapy for systemic mastocytosis","volume":"102","author":"Kluin-Nelemans","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2021.06.011_bib91","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJM200101253440415","article-title":"Treatment of systemic mast-cell disease with cladribine","volume":"344","author":"Tefferi","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.06.011_bib92","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1182\/blood-2015-06-649525","article-title":"Cladribine for mastocytosis: benefits and risks","volume":"126","author":"Akin","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2021.06.011_bib93","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2015.242","article-title":"Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth","volume":"30","author":"Peter","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jaip.2021.06.011_bib94","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1093\/annonc\/mdx290","article-title":"Midostaurin: a magic bullet that blocks mast cell expansion and activation","volume":"28","author":"Valent","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaip.2021.06.011_bib95","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/all.12436","article-title":"Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis","volume":"69","author":"Valent","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.06.011_bib96","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jaci.2014.05.047","article-title":"Diminished reliability of tryptase as risk indicator of mastocytosis in older overweight subjects","volume":"135","author":"Vos","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib97","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.iac.2015.01.010","article-title":"Mast cell activation syndromes presenting as anaphylaxis","volume":"35","author":"Akin","year":"2015","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2021.06.011_bib98","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature14022","article-title":"Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions","volume":"519","author":"McNeil","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jaip.2021.06.011_bib99","doi-asserted-by":"crossref","first-page":"9030","DOI":"10.3390\/ijms21239030","article-title":"Diagnosis, classification and management of mast cell activation syndromes (MCAS) in the era of personalized medicine","volume":"21","author":"Valent","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaip.2021.06.011_bib100","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaci.2008.11.018","article-title":"Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels","volume":"123","author":"Bonadonna","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib101","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.jaip.2017.02.008","article-title":"Risk factor analysis of anaphylactic reactions in patients with systemic mastocytosis","volume":"5","author":"Gulen","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.06.011_bib102","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.iac.2016.08.017","article-title":"Mastocytosis and anaphylaxis","volume":"37","author":"Schuch","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2021.06.011_bib103","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1016\/j.jaip.2020.05.044","article-title":"Low frequency of IgE-mediated food hypersensitivity in mastocytosis","volume":"8","author":"Jarkvist","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.06.011_bib104","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/ACI.0b013e328355b7cb","article-title":"Drug allergy in mast cell disease","volume":"12","author":"Brockow","year":"2012","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib105","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jaci.2018.10.063","article-title":"Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: a Work Group Report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma & Immunology","volume":"143","author":"Carter","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib106","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jaip.2013.06.014","article-title":"Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations","volume":"1","author":"Bonadonna","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.06.011_bib107","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/all.13980","article-title":"Venom immunotherapy in patients with clonal mast cell disorders: IgG4 correlates with protection","volume":"75","author":"Jarkvist","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.06.011_bib108","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/all.13187","article-title":"Prospective evaluation of the diagnostic value of sensitive KIT D816V mutation analysis of blood in adults with suspected systemic mastocytosis","volume":"72","author":"Kristensen","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.06.011_bib109","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jaci.2014.06.031","article-title":"Recognizing mastocytosis in patients with anaphylaxis: value of KIT D816V mutation analysis of peripheral blood","volume":"135","author":"Broesby-Olsen","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib110","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jaci.2010.02.019","article-title":"Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms","volume":"125","author":"Alvarez-Twose","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib111","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jaci.2017.05.036","article-title":"A\u00a0distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis","volume":"141","author":"Carter","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib112","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1385\/COMP:31:1:059","article-title":"Disorders of flushing","volume":"31","author":"Yale","year":"2005","journal-title":"Compr Ther"},{"key":"10.1016\/j.jaip.2021.06.011_bib113","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1590\/S0004-27302005000500028","article-title":"Carcinoid syndrome: diagnosis and medical management","volume":"49","author":"Van der Lely","year":"2005","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"10.1016\/j.jaip.2021.06.011_bib114","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.jaad.2006.07.008","article-title":"Flushing, pheochromocytoma, and the dermatologist","volume":"55","author":"Heymann","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2021.06.011_bib115","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000382053","article-title":"Clinical syndromes related to gastrointestinal neuroendocrine neoplasms","volume":"44","author":"Boutzios","year":"2015","journal-title":"Front Horm Res"},{"key":"10.1016\/j.jaip.2021.06.011_bib116","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40257-015-0144-6","article-title":"The dermatological manifestations of postural tachycardia syndrome: a review with illustrated cases","volume":"16","author":"Huang","year":"2015","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaip.2021.06.011_bib117","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s11154-016-9394-8","article-title":"Flushing in (neuro)endocrinology","volume":"17","author":"Hannah-Shmouni","year":"2016","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.jaip.2021.06.011_bib118","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3121\/cmr.2017.1379a","article-title":"Flushing disorders associated with gastrointestinal symptoms: Part 1, neuroendocrine tumors, mast cell disorders and hyperbasophila","volume":"16","author":"Rastogi","year":"2018","journal-title":"Clin Med Res"},{"key":"10.1016\/j.jaip.2021.06.011_bib119","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jaip.2018.11.045","article-title":"Doctor, I think I am suffering from MCAS: differential diagnosis and separating facts from fiction","volume":"7","author":"Valent","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.06.011_bib120","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.jaci.2013.11.039","article-title":"Mendelian inheritance of elevated serum tryptase associated with atopy and connective tissue abnormalities","volume":"133","author":"Lyons","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib121","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/ng.3696","article-title":"Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number","volume":"48","author":"Lyons","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaip.2021.06.011_bib122","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.jaci.2020.11.017","article-title":"Patients with mast cell activation symptoms and elevated baseline serum tryptase level have unique bone marrow morphology","volume":"147","author":"Giannetti","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib123","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/PAS.0000000000001676","article-title":"Distinct small intestine mast cell histologic changes in patients with hereditary alpha-tryptasemia and mast cell activation syndrome","volume":"45","author":"Hamilton","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jaip.2021.06.011_bib124","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1016\/j.jaip.2020.05.057","article-title":"Hereditary alpha-tryptasemia: UK prevalence and variability in disease expression","volume":"8","author":"Robey","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.06.011_bib125","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.iac.2018.04.003","article-title":"Hereditary alpha tryptasemia: genotyping and associated clinical features","volume":"38","author":"Lyons","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2021.06.011_bib126","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11882-019-0887-x","article-title":"Mast cell activation in the context of elevated basal serum tryptase: genetics and presentations","volume":"19","author":"Khoury","year":"2019","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaip.2021.06.011_bib127","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/ACI.0000000000000678","article-title":"Hymenoptera venom-induced anaphylaxis and hereditary alpha-tryptasemia","volume":"20","author":"O'Connell","year":"2020","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib128","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1084\/jem.20190701","article-title":"Impact of naturally forming human \u03b1\/\u03b2-tryptase heterotetramers in the pathogenesis of hereditary \u03b1-tryptasemia","volume":"216","author":"Le","year":"2019","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jaip.2021.06.011_bib129","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaci.2020.06.035","article-title":"Heritable risk for severe anaphylaxis associated with increased \u03b1-tryptase-encoding germline copy number at TPSAB1","volume":"147","author":"Lyons","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib130","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10875-018-0506-y","article-title":"First identification of an inherited TPSAB1 quintuplication in a patient with clonal mast cell disease","volume":"38","author":"Sabato","year":"2018","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib131","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.jaci.2014.06.007","article-title":"Familial hypertryptasemia with associated mast cell activation syndrome","volume":"134","author":"Sabato","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.06.011_bib132","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3109\/07853890.2016.1161231","article-title":"Often seen, rarely recognized: mast cell activation disease\u2014a guide to diagnosis and therapeutic options","volume":"48","author":"Afrin","year":"2016","journal-title":"Ann Med"},{"key":"10.1016\/j.jaip.2021.06.011_bib133","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/PAS.0000000000000190","article-title":"A\u00a0clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients","volume":"38","author":"Doyle","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jaip.2021.06.011_bib134","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.iac.2018.04.006","article-title":"Patient perceptions in mast cell disorders","volume":"38","author":"Jennings","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2021.06.011_bib135","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jaip.2018.07.032","article-title":"The Mastocytosis Society Survey on Mast Cell Disorders: Part 2\u2013Patient clinical experiences and beyond","volume":"7","author":"Russell","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.06.011_bib136","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13256-017-1278-3","article-title":"Continuous diphenhydramine infusion and imatinib for KIT-D816V-negative mast cell activation syndrome: a case report","volume":"11","author":"Malik","year":"2017","journal-title":"J\u00a0Med Case Rep"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219821006760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219821006760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:31:22Z","timestamp":1761975082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219821006760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":136,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S2213219821006760"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2021.06.011","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2021.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}